These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The hunt for a cure for Parkinson's disease. Andersen JK; Kumar J; Srinivas B; Kaur D; Hsu M; Rajagopalan S Sci Aging Knowledge Environ; 2001 Oct; 2001(1):re1. PubMed ID: 14602952 [TBL] [Abstract][Full Text] [Related]
7. The anatomy of the basal ganglia and Parkinson's disease: a review. Lee TK; Chau R; Leong SK Singapore Med J; 1995 Feb; 36(1):74-6. PubMed ID: 7570141 [TBL] [Abstract][Full Text] [Related]
8. Functional neuroanatomy of the basal ganglia in Parkinson's disease. Wichmann T; DeLong MR Adv Neurol; 2003; 91():9-18. PubMed ID: 12442660 [No Abstract] [Full Text] [Related]
9. Understanding the dopaminergic deficits in Parkinson's disease: insights into disease heterogeneity. Lewis SJ; Barker RA J Clin Neurosci; 2009 May; 16(5):620-5. PubMed ID: 19285870 [TBL] [Abstract][Full Text] [Related]
10. [A new history of basal ganglia and physiopathology of Parkinson's disease]. Reinoso Suárez F An R Acad Nac Med (Madr); 2001; 118(4):771-88; discussion 788-92. PubMed ID: 12056254 [TBL] [Abstract][Full Text] [Related]
13. [Striato-cerebellar degeneration in a case of Parkinson's syndrome]. Bignami A Acta Neurol (Napoli); 1967; 22(2):274-80. PubMed ID: 5606832 [No Abstract] [Full Text] [Related]
14. Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Nakano I; Hirano A Ann Neurol; 1984 May; 15(5):415-8. PubMed ID: 6732189 [TBL] [Abstract][Full Text] [Related]
15. Dysfunction of the basal ganglia, but not the cerebellum, impairs kinaesthesia. Maschke M; Gomez CM; Tuite PJ; Konczak J Brain; 2003 Oct; 126(Pt 10):2312-22. PubMed ID: 12821507 [TBL] [Abstract][Full Text] [Related]
16. New developments of brain imaging for Parkinson's disease and related disorders. Piccini P; Brooks DJ Mov Disord; 2006 Dec; 21(12):2035-41. PubMed ID: 16874751 [TBL] [Abstract][Full Text] [Related]
17. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease. Liu B; Dluzen DE Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209 [TBL] [Abstract][Full Text] [Related]
18. Levodopa delivery systems for the treatment of Parkinson's disease: an overview. Goole J; Amighi K Int J Pharm; 2009 Oct; 380(1-2):1-15. PubMed ID: 19651197 [TBL] [Abstract][Full Text] [Related]